Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Signum Biosciences, a biotechnology company, has signed investment and licensing agreements with Rohto Pharmaceutical Co of Osaka, Japan, a manufacturer and marketer of skincare, pharmaceutical and other healthcare related products.
Subscribe to our email newsletter
The agreements, which provide Signum with combined upfront license fees and investment funds in the seven figures, give Rohto a non-exclusive right to develop and sell products in Japan that contain Signum’s anti-inflammatory compound Arazine, the lead molecule involving the company’s signal transduction modulation technology.
The parties have agreed to immediately enter negotiations for an exclusive license for the Japanese market. Rohto and Signum also have undertaken a broad R&D collaboration to develop an array of Arazine based products that draw on the compound’s triple-action capabilities.
Gregory Stock, CEO of Signum, said: “Rohto is an ideal partner to develop skincare products using our signal transduction modulation technology. They have a strong emphasis on quality, they excel at product development, and the Japanese consumer is very discerning. Our collaboration will produce exciting products in 2009 that open up a new category of skincare agents.”